rs397508075 — KCNQ1 KCNQ1 Long QT Type 1 Variant 3

KCNQ1 Q359X — When a Premature Stop Codon Silences the Heart's Repolarization Safety Valve

The heart's electrical rhythm depends on a precisely timed cascade of ion channel openings and closings. After each beat, the muscle must rapidly repolarize — reset its electrical charge — to be ready for the next. One of the key channels driving this repolarization is the IKs current¹¹ IKs current
The slow component of the delayed rectifier potassium current — encoded by KCNQ1 (the α subunit) in combination with KCNE1 (the β subunit) — is the dominant repolarizing current at fast heart rates and during adrenergic stimulation, encoded by KCNQ1. The rs397508075 variant introduces a premature stop codon at position 359 of the 676-amino-acid KCNQ1 protein, truncating more than 45% of the channel before it reaches its C-terminal assembly and trafficking domains.

The Mechanism

KCNQ1 is located on the plus strand of chromosome 11 (11p15.5). The c.1075C>T change converts a glutamine codon (CAG) to a stop codon (TAG) at amino acid position 359, within the third intracellular loop of the channel protein. This truncation is predicted to eliminate the protein entirely through [nonsense-mediated mRNA decay | A cellular surveillance mechanism that degrades mRNAs containing premature stop codons more than ~50–55 nucleotides upstream of the last exon-exon junction. KCNQ1 Q359X satisfies this criterion, making protein-level truncation unlikely — the mRNA itself is degraded before translation is complete], rather than producing a dominant-negative truncated protein. The result is [haploinsufficiency | Only one functional copy of KCNQ1 remains, producing roughly half the normal IKs current density]: heterozygous carriers produce approximately 50% of normal IKs current.

Under resting conditions, 50% IKs is often sufficient for normal or near-normal QT intervals — many heterozygous carriers have QTc values only modestly prolonged (460–500 ms). But during [adrenergic stimulation | Activation of the sympathetic nervous system during exercise, excitement, startle, or emotional stress triggers catecholamine release. Catecholamines activate PKA, which phosphorylates KCNQ1 and normally produces a several-fold increase in IKs current to accelerate repolarization at fast heart rates], the demand for IKs increases dramatically — and the haploinsufficient channel cannot meet it. The result is a dangerously prolonged action potential at precisely the moments when the heart is beating fastest: during a race, a swim, or a moment of sudden fright.

The Evidence

Long QT syndrome type 1 (LQT1) is the most common form of inherited LQTS, accounting for approximately 35–45% of genetically confirmed cases. The evidence base for KCNQ1 loss-of-function variants is among the most developed in cardiac genetics.

A landmark Circulation study of 216 genotyped LQT1 patients followed for a median of 10 years²² Circulation study of 216 genotyped LQT1 patients followed for a median of 10 years
Vincent et al. 2009 — high efficacy of β-blockers in LQT1 found that 75% of patients treated with beta-blockers remained asymptomatic throughout follow-up, and cardiac events were reduced by 64%. Crucially, essentially all treatment failures occurred in patients who were either non-compliant with therapy or had taken QT-prolonging drugs — not in patients faithfully on beta-blockers and avoiding triggers.

Mutation location matters for risk stratification. A 600-patient analysis of 77 KCNQ1 mutations³³ 600-patient analysis of 77 KCNQ1 mutations
Moss et al. 2007, Circulation — clinical aspects by location, coding type, and biophysical function found that transmembrane-domain mutations and those producing severe dominant-negative channel dysfunction carry the highest event rates; C-terminal and loss-of-function mutations including nonsense variants carry intermediate-to-lower risk.

This is supported by a 1,090-patient Heart Rhythm study of mutation coding type⁴⁴ 1,090-patient Heart Rhythm study of mutation coding type
Earle et al. 2016 — stop-codon mutations associated with lower risk in LQT1 which found that stop-codon mutations, including Q-type nonsense variants in KCNQ1, were associated with a hazard ratio of 0.57 (95% CI 0.34–0.96) for cardiac events versus non-c-loop missense mutations. A possible mechanism: haploinsufficient channels may partially rescue current amplitude relative to dominant-negative mutants that poison all assembled tetramers.

Despite lower relative risk, the absolute risk of untreated LQT1 remains clinically significant. Barsheshet et al. 2012⁵⁵ Barsheshet et al. 2012
Mutations in cytoplasmic loops and risk of life-threatening events — PMID 22456477 confirmed that even the lower-risk non-c-loop KCNQ1 mutations carry meaningful event rates, with 10–15% of carriers experiencing syncope or aborted cardiac arrest by age 40 without treatment.

Practical Actions

The cornerstone of LQT1 management is beta-blocker therapy. Nadolol is the preferred agent — it is the only beta-blocker shown to reduce events in both LQT1 and LQT2, and outperforms propranolol and atenolol in network meta-analyses. Metoprolol has shown no significant risk reduction for LQT1 in the registry data and should be avoided as the primary LQT1 agent.

Trigger avoidance is LQT1-specific: swimming and water sports carry unique danger because the combined effects of immersion (vagal activation), exertion (adrenergic activation), and sudden startle (dive reflex) create compounded arrhythmia risk. Competitive swimming is specifically contraindicated in previously symptomatic LQT1 carriers by AHA/ACC guidelines.

QT-prolonging drugs represent the second major modifiable trigger. The crediblemeds.org database (accessible free of charge) maintains the current list of >200 drugs in the highest-risk category. These span antibiotics (fluoroquinolones, macrolides), antihistamines, antipsychotics, antidepressants, antifungals, and several antiarrhythmics themselves.

ICD therapy is reserved for survivors of cardiac arrest, those with syncope despite adequate beta-blocker therapy, and selected very high-risk patients (QTc >550 ms, T-wave alternans). It is not the first-line approach for newly diagnosed asymptomatic carriers.

Cascade screening of first-degree relatives is essential — each has a 50% probability of inheriting the same variant, and the condition is largely manageable if identified before the first event.

Interactions

KCNQ1 assembles with KCNE1 (MinK) as β-subunit to form the complete IKs channel complex. Loss-of-function mutations in KCNE1 (rs74315445 and related KCNE1 variants, gene OMIM 176261) produce a clinically indistinguishable LQT phenotype (LQT5). Compound heterozygosity for KCNQ1 and KCNE1 variants in the same individual increases IKs impairment beyond either alone. Homozygous or compound heterozygous KCNQ1 mutations — or biallelic KCNQ1 + KCNE1 — cause Jervell and Lange-Nielsen syndrome⁶⁶ Jervell and Lange-Nielsen syndrome
A recessive form of LQTS combined with congenital profound sensorineural deafness. QTc is typically >550 ms and the risk of sudden cardiac death in childhood is very high without ICD implantation, which presents with profound deafness and a much more severe cardiac phenotype (mean QTc ~557 ms, >90% cardiac event rate).

Electrolyte depletion — particularly hypokalemia and hypomagnesemia — further impairs IKs function and acutely lengthens QT in carriers. Diuretics (loop and thiazide), vomiting, diarrhea, and heat-related dehydration are practical clinical triggers that interact with the genetic predisposition.